Skip to main content


Figure 1 | BMC Research Notes

Figure 1

From: Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

Figure 1

Observed mean eGFR (± SD) over time by treatment group in the RCTs. Mean eGFR was determined every 6 weeks for patients in each of the randomized treatment groups (pegloticase infused every 2 weeks, pegloticase infused every 4 weeks alternating with placebo, and placebo) during the 6-month trials. PGL = pegloticase, SD = standard deviation, eGFR = estimated glomerular filtration rate.

Back to article page